Company intelligence / Profile preview

Bioprojet Biotech

Paris, Ile-de-France, Francebioprojet.com ↗

Ownership: Private
Employees: ~152
Development stage: Commercial

Overview

Bioprojet has successfully developed several "First in Class" drugs including racecadotril (enkephalinase inhibitor), pitolisant (H3 histamine receptor inverse agonist/antagonist), and BP1.4979 (partial agonist of D3 dopamine receptor). Their flagship product Wakix (pitolisant) is approved for narcolepsy treatment in Europe and the US, including for children over 6 years of age as of March 2023.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BS6.890C

Preclinical

Partnerships

Harmony Biosciences (licensing agreement for pitolisant in the US)

Beyond the preview

Go deeper on Bioprojet Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioprojet Biotech.

Explore the full profile